Dermatologic Toxicities

  • Eugene Balagula
  • Mario E. Lacouture


Patients diagnosed with cancer will face many toxicities of chemotherapy, radiation, or their combination. Numerous dermatological toxicities associated with these treatments range from mild discomfort to being potentially life-threatening. Side effects leading to significant discomfort can result in decreased quality of life and dose reduction or treatment interruption, compromising the efficacy of treatment with negative impact on morbidity and mortality. A variety of adverse effects such as alopecia, mucositis, and systemic toxicities associated with conventional cytotoxic agents have been well-described, but with the advent of novel targeted agents, a variety of new dermatologic side effects have emerged. Toxicities affecting skin and its adnexae (i.e., hair, nails) such as, hand–foot skin reaction, papulopustular rash, and paronychia may present both diagnostic and management dilemmas for health-care providers. Although many antitoxicity interventions have not been examined by randomized studies, there are ways of mitigating these untoward events in clinical practice. This chapter will address a variety of skin and nail toxicities induced by both conventional and targeted chemotherapy agents and will describe adverse effects associated with radiotherapy. Proposed underlying mechanisms will be reviewed and special attention will be directed to management strategies that are available to date.


Graft Versus Host Disease Toxic Epidermal Necrolysis Skin Toxicity Stevens Johnson Syndrome Pegylated Liposomal Doxorubicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lynch TJ, Jr., Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610–621.PubMedCrossRefGoogle Scholar
  2. 2.
    Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345–356.PubMedCrossRefGoogle Scholar
  3. 3.
    Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001–1011.PubMedCrossRefGoogle Scholar
  4. 4.
    Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4: 107–119.PubMedCrossRefGoogle Scholar
  5. 5.
    Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536–3544.PubMedCrossRefGoogle Scholar
  6. 6.
    Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16: 16–26.PubMedCrossRefGoogle Scholar
  7. 7.
    Mitchell EP, Lacouture ME, Shearer H, et al. A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic ­colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT as 2nd-line ­treatment (tx): Interim analysis. J Clin Oncol 2008; (abstract 15007): 644s.Google Scholar
  8. 8.
    Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390–5396.PubMedCrossRefGoogle Scholar
  9. 9.
    Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113: 847–853.PubMedCrossRefGoogle Scholar
  10. 10.
    Lacouture ME, Basti S, Patel J, Benson A, 3rd. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006; 4: 236–238.PubMedGoogle Scholar
  11. 11.
    Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955–1961.PubMedCrossRefGoogle Scholar
  12. 12.
    Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47: 176–186.PubMedCrossRefGoogle Scholar
  13. 13.
    Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58: 545–570.PubMedCrossRefGoogle Scholar
  14. 14.
    Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (’hand-foot’ syndrome). Ann Oncol 2007; 18: 1159–1164.PubMedCrossRefGoogle Scholar
  15. 15.
    Janusch M, Fischer M, Marsch W, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome – a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006; 16: 494–499.PubMedGoogle Scholar
  16. 16.
    von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, Lademann J, Hauschild A. Pegylated liposomal doxorubicin-­associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008; 44: 781–790.CrossRefGoogle Scholar
  17. 17.
    Brown J, Burck K, Black D, Collins C. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 1991; 24: 1023–1025.PubMedCrossRefGoogle Scholar
  18. 18.
    Agha R, Kinahan K, Bennett CL, Lacouture ME. Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park) 2007; 21: 1462–1472; discussion 1473, 1476, 1481 passim.Google Scholar
  19. 19.
    Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006; 7: 45–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598–605.PubMedCrossRefGoogle Scholar
  21. 21.
    Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92–96.PubMedCrossRefGoogle Scholar
  22. 22.
    French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55: 9–16.PubMedCrossRefGoogle Scholar
  23. 23.
    J. Sorrell, D. P. West, C. L. Bennett, D. W. Raisch, Lacouture ME. Life-threatening dermatologic toxicities to cancer drug therapy: An assessment of the published peer-reviewed literature. J Clin Oncol 2009; 27: (suppl; abstr e20592).Google Scholar
  24. 24.
    Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med 2008; 40: 129–138.PubMedCrossRefGoogle Scholar
  25. 25.
    Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009; 19: 90–98.PubMedGoogle Scholar
  26. 26.
    Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491–500.PubMedCrossRefGoogle Scholar
  27. 27.
    Kim RJ, Peterson G, Kulp B, Zanotti KM, Markman M. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 2005; 97: 374–378.PubMedCrossRefGoogle Scholar
  28. 28.
    Guillot B, Bessis D, Dereure O. Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf 2004; 3: 579–587.PubMedCrossRefGoogle Scholar
  29. 29.
    Sanborn RE, Sauer DA. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin 2008; 26: 103–119, ix.Google Scholar
  30. 30.
    Nellen RG, van Marion AM, Frank J, Poblete-Gutierrez P, Steijlen PM. Eruption of lymphocyte recovery or autologous graft-versus-host disease? Int J Dermatol 2008; 47 Suppl 1: 32–34.PubMedCrossRefGoogle Scholar
  31. 31.
    Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550–1561.PubMedCrossRefGoogle Scholar
  32. 32.
    Hausermann P, Walter RB, Halter J, Biedermann BC, Tichelli A, Itin P, Gratwohl A. Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology 2008; 216: 287–304.PubMedCrossRefGoogle Scholar
  33. 33.
    Bates JS, Engemann AM, Hammond JM. Clinical utility of rituximab in chronic graft-versus-host disease. Ann Pharmacother 2009; 43: 316–321.PubMedGoogle Scholar
  34. 34.
    Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33: 86–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Lacouture ME, Hwang C, Marymont MH, Patel J. Temporal dependence of the effect of radiation on erlotinib-induced skin rash. J Clin Oncol 2007; 25: 2140; author reply 2141.Google Scholar
  36. 36.
    Bolderston A, Lloyd NS, Wong RK, Holden L, Robb-Blenderman L. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 2006; 14: 802–817.PubMedCrossRefGoogle Scholar
  37. 37.
    Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19: 142–149.PubMedCrossRefGoogle Scholar
  38. 38.
    Schmuth M, Wimmer MA, Hofer S, Sztankay A, Weinlich G, Linder DM, Elias PM, Fritsch PO, Fritsch E. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol 2002; 146: 983–991.PubMedCrossRefGoogle Scholar
  39. 39.
    Bostrom A, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol 2001; 59: 257–265.PubMedCrossRefGoogle Scholar
  40. 40.
    Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009; 115: 1286–1299.PubMedCrossRefGoogle Scholar
  41. 41.
    Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6: 431–443.PubMedCrossRefGoogle Scholar
  42. 42.
    Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD. Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 2007; 56: 494–499.PubMedCrossRefGoogle Scholar
  43. 43.
    Lacouture ME, Boerner SA, Lorusso PM. Non-rash skin toxicities associated with novel targeted therapies. Clin Lung Cancer 2006; 8 Suppl 1: S36–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–1433.PubMedCrossRefGoogle Scholar
  45. 45.
    Villalon G, Martin JM, Pinazo MI, Calduch L, Alonso V, Jorda E. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine. Am J Clin Dermatol 2009; 10: 261–263.PubMedCrossRefGoogle Scholar
  46. 46.
    Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7: 20–23.PubMedCrossRefGoogle Scholar
  47. 47.
    Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 2009; 15: 143–155.PubMedCrossRefGoogle Scholar
  48. 48.
    Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to daily biotin supplementation. Cutis 1993; 51: 303–305.PubMedGoogle Scholar
  49. 49.
    Hammond-Thelin LA. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 2008; 26: 121–159, ix.Google Scholar
  50. 50.
    Roh MR, Cho JY, Lew W. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration. Yonsei Med J 2007; 48: 124–126.PubMedCrossRefGoogle Scholar
  51. 51.
    Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23: 4424–4429.PubMedCrossRefGoogle Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  1. 1.Department of DermatologyMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations